文献速递眼整形与眼眶

Idelalisib抑制体外甲状腺眼病模型中的脂肪生成

Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

本研究发现,选择性PI3Kδ抑制剂idelalisib在体外甲状腺眼病(GO)眼眶成纤维细胞中抑制AKT磷酸化,减少IL-1β诱导的IL-6和IL-8表达,并抑制脂肪分化过程中的脂滴形成及PPARγ和C/EBPα/β表达,提示PI3K抑制剂可能用于GO管理。

要点

  • Idelalisib剂量依赖性抑制GO和非GO眼眶成纤维细胞中AKT磷酸化。
  • Idelalisib抑制IL-1β诱导的IL-6和IL-8表达。
  • Idelalisib减少脂肪分化中的脂滴及PPARγ和C/EBPα/β表达。

核心结论

  • Idelalisib在体外抑制GO眼眶成纤维细胞的促炎细胞因子产生和脂肪生成,支持PI3K抑制剂用于GO管理的潜力。

研究设计与样本

  • 体外研究:从GO患者和健康对照者的眼眶结缔组织培养眼眶成纤维细胞,用idelalisib预处理1小时后以IL-1β刺激。

主要发现

  • Idelalisib剂量依赖性降低GO和非GO眼眶成纤维细胞的AKT磷酸化。
  • Idelalisib抑制IL-1β诱导的IL-6和IL-8表达。
  • Idelalisib减弱mTOR和FOXO1的磷酸化。
  • Oil Red O染色显示idelalisib处理减少脂滴,并抑制PPARγ和C/EBPα/β表达。

临床怎么用

  • 体外证据提示PI3Kδ抑制剂可能作为GO的潜在治疗方向,但尚需临床研究验证。

局限性

  • 研究为体外细胞模型,未涉及体内疗效和安全性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Emerging evidence indicates that the phosphatidylinositol 3-kinase (PI3K)-AKT pathway is involved in the pathogenesis of Graves' orbitopathy (GO). In this study, the therapeutic effects of idelalisib, a selective PI3Kδ inhibitor, on adipogenesis were evaluated in GO orbital fibroblasts in vitro. METHODS: Orbital fibroblasts were cultured from orbital connective tissues obtained from individuals with GO and healthy control subjects. Cells were pretreated with idelalisib for 1 hour before stimulation with IL-1β. Inflammatory cytokine expression was measured by Western blotting and ELISAs. The adipogenesis-related downstream mediators of the PI3K/AKT cascade, that is, forkhead box protein O1 (FOXO1) and mammalian target of rapamycin (mTOR), also were measured by Western blotting. After adipogenic differentiation and idelalisib treatment, cells were stained with Oil Red O and the levels of peroxisome proliferator activator γ (PPARγ) and CCAAT-enhancer-binding proteins (C/EBP) α/β were determined by Western blot analyses. RESULTS: AKT phosphorylation decreased in a dose-dependent manner upon treatment with idelalisib in GO and non-GO orbital fibroblasts. Treatment with idelalisib inhibited the IL-1β-induced expression of IL-6 and IL-8. Idelalisib attenuated the phosphorylation of mTOR and FOXO1, downstream regulators of the PI3K pathway. Oil Red-O staining results revealed a decrease in lipid droplets and suppressed expression of PPARγ and c/EBPα/β upon treatment with idelalisib during adipose differentiation. CONCLUSIONS: Idelalisib inhibited proinflammatory cytokine production and adipogenesis in GO orbital fibroblasts in vitro. These results support the potential use of PI3K inhibitors in GO management.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ko J, Kim JY, Lee EJ, et al. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy. Invest Ophthalmol Vis Sci. 2018. PMID: 30193323. doi:10.1167/iovs.18-24509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。